Oncologists need education on rituximab screening tests, liver specialists say

Patients receiving immunosuppressive therapy are being put at risk of severe hepatitis flares and liver failure because they are not being  tested for hepatitis B infection prior to starting therapy, a South Australian study shows. Although screening is recommended in guidelines to avoid reactivation of hepatitis B infection  by immunomodulator drugs, only about half of patients taking ...

Already a member?

Login to keep reading.

© 2021 the limbic